Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hybridoma Technology01:31

Hybridoma Technology

14.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.9K
Antibody Actions01:26

Antibody Actions

1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Antibody Structure01:10

Antibody Structure

60.3K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.3K
Humoral Immune Responses01:36

Humoral Immune Responses

73.0K
Overview
73.0K
Antibody Structure and Classes01:25

Antibody Structure and Classes

957
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
957
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

54
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
54

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Bacterial Glutamine Synthetases as a Novel Metabolic Selection Marker to Improve CHO Cell Culture Performance Through Selection Stringency Modulation.

Biotechnology journal·2025
Same author

Deep learning-based design and experimental validation of a medicine-like human antibody library.

Briefings in bioinformatics·2025
Same author

Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions.

Cell reports·2024
Same author

Biophysics of claudin proteins in tight junction architecture: Three decades of progress.

Biophysical journal·2024
Same author

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based <i>in silico</i> approaches.

mAbs·2024
Same author

Geometric Antibody Engineering Reveals the Spatial Factor on the Efficacy of Bispecific T Cell Engagers.

ACS chemical biology·2024

相关实验视频

Updated: Jul 18, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.5K

我们如何能够发现可开发的抗体基生物疗法?

Joschka Bauer1,2, Nandhini Rajagopal2,3, Priyanka Gupta2,3

  • 1Early Stage Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany.

Frontiers in molecular biosciences
|August 23, 2023
PubMed
概括

生物制药信息学整合了计算和实验,以克服抗体药物发现的挑战. 这种方法可以加速为患者开发安全有效的抗体治疗方法.

关键词:
生物制药信息学 生物制药信息学生物治疗药物 生物治疗药物计算生物物理学的计算生物物理.开发能力 开发能力药物的发现和开发.机器学习是机器学习.

更多相关视频

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity
12:31

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Published on: May 1, 2018

13.8K
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.6K

相关实验视频

Last Updated: Jul 18, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.5K
Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity
12:31

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Published on: May 1, 2018

13.8K
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.6K

科学领域:

  • 生物制药信息学 生物制药信息学
  • 抗体 药物发现 药物发现
  • 计算生物学 计算生物学

背景情况:

  • 基于抗体的生物疗法是一种成功但具有挑战性的制药类.
  • 这些复杂药物的研发存在重大障碍.

研究的目的:

  • 提出生物制药信息学作为解决研发挑战的框架.
  • 倡导在整个生物药物发现过程中整合计算和实验.
  • 在发现阶段的早期考虑药物开发能力.

主要方法:

  • 对抗原优化和免疫反应的计算方法的审查.
  • 在体抗体序列生成和虚拟查的分析.
  • 评估用于领先候选人识别和亲和力成熟的计算方法.

主要成果:

  • 计算进步使得疾病概念的准确制定和目标识别成为可能.
  • 新兴的计算方法促进了de novo和表位特异性抗体设计.
  • 虚拟查和计算评估有助于发现和优化抗体结合剂.

结论:

  • 生物制药信息学提供了克服抗体研发局限性的机会.
  • 整合计算策略可以提高候选人选择和开发能力.
  • 采用这种框架可以加快提供负担得起,有效的生物疗法.